Following on from information provided to NICE by the company in May 2018 the appraisal of Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1298 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2018 the appraisal of Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 July 2018 | Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab for treating metastatic colorectal cancer after 2 therapies. However, the company have advised that the Phase III IMblaze370 trial has failed to reach its primary end point in showing an improvement in overall survival compared to regorafenib and they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes |
| 01 June 2018 | Suspended. Suspended |
| 26 April 2018 - 25 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 17 May 2018 | The National Institute for Health and Care Excellence has been asked to conduct an appraisal of atezolizumab for treating locally advanced or metastatic colorectal cancer after 2 therapies We have recently invited stakeholders to respond to a written consultation on the draft scope for this topic. The company that market atezolizumab have shared confidential information with NICE, in light of this information NICE will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will stop. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email on michelle.adhemar@nice.org.uk |
| 11 August 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual